Prophase Labs Stock Performance
| PRPH Stock | USD 4.90 0.36 6.84% |
ProPhase Labs has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of -0.36, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ProPhase Labs are expected to decrease at a much lower rate. During the bear market, ProPhase Labs is likely to outperform the market. ProPhase Labs right now holds a risk of 4.72%. Please check ProPhase Labs value at risk, as well as the relationship between the skewness and day median price , to decide if ProPhase Labs will be following its historical price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in ProPhase Labs are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong basic indicators, ProPhase Labs is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 9.1 M | |
| Free Cash Flow | -14.5 M |
ProPhase |
ProPhase Labs Relative Risk vs. Return Landscape
If you would invest 503.00 in ProPhase Labs on January 24, 2024 and sell it today you would lose (13.00) from holding ProPhase Labs or give up 2.58% of portfolio value over 90 days. ProPhase Labs is currently generating 0.0675% in daily expected returns and assumes 4.7181% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than ProPhase, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProPhase Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProPhase Labs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProPhase Labs, and traders can use it to determine the average amount a ProPhase Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0143
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | PRPH | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.72 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average ProPhase Labs is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProPhase Labs by adding it to a well-diversified portfolio.
ProPhase Labs Fundamentals Growth
ProPhase Stock prices reflect investors' perceptions of the future prospects and financial health of ProPhase Labs, and ProPhase Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProPhase Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (3.24) % | ||||
| Current Valuation | 111.56 M | ||||
| Shares Outstanding | 18.05 M | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 2.38 X | ||||
| Price To Sales | 2.65 X | ||||
| Revenue | 44.38 M | ||||
| EBITDA | (14.91 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 21.38 M | ||||
| Debt To Equity | 0.19 % | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (11.35 M) | ||||
| Earnings Per Share | (0.98) X | ||||
| Total Asset | 91.93 M | ||||
| Retained Earnings | (5.03 M) | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
About ProPhase Labs Performance
To evaluate ProPhase Labs Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ProPhase Labs generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ProPhase Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ProPhase Labs market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ProPhase's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people.Things to note about ProPhase Labs performance evaluation
Checking the ongoing alerts about ProPhase Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProPhase Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProPhase Labs had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 44.38 M. Net Loss for the year was (16.78 M) with profit before overhead, payroll, taxes, and interest of 70.65 M. | |
| ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing ProPhase Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProPhase Labs' stock is overvalued or undervalued compared to its peers.
- Examining ProPhase Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProPhase Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProPhase Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProPhase Labs' stock. These opinions can provide insight into ProPhase Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is ProPhase Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.